Sign in

Jan T Kielstein, MD

@jtkidney.bsky.social
65 followers 38 following 78 posts

2nd generation #kidney doctor with a passion to make #dialysis #bloodpurification technology available to all in need. #GENIUS for green dialysis.

PostsRepliesMedia
Jan T Kielstein, MD @jtkidney.bsky.social · 08/09/2026
Forget „one dose fits all“. If you increase the dose #KRT (kidney replacement therapy) in critically ill patients you need to increase the dose of #vancomycin. Best dosing recommendations available. link.springer.com/article/10.1...
link.springer.com
Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy - Critical Care
Background Optimal dosing of vancomycin in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to high pharmacokinetic variability. We aimed to develop individualised va...
001
Jan T Kielstein, MD @jtkidney.bsky.social · 19/08/2026
It’s time to include #UACR and #eGFR into our occupational health screening. The seminal paper by Angela Stefano and co-workers showed that it makes sense to look for #CKD even in asymptomatic adults aged 19-30. Compelling data in 12,281 subjects. academic.oup.com/ckj/article/...
academic.oup.com
Asymptomatic kidney changes discovered during occupational health screening: age-dependent trends from a large cohort
ABSTRACTBackground. The urinary albumin-to-creatinine ratio (uACR) and estimated glomerular filtration rate (eGFR) are key biomarkers for asymptomatic dete
010
Reposted by Jan T Kielstein, MD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 21/07/2026
The #NephJC interns @manoleaandreea.bsky.social and @divyaveerssneph.bsky.social dissect the FINDCKD study from @brendonneuen.bsky.social et al www.nephjc.com/news/2026/7/...
nephjc.com
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role — NephJC
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...
173
Jan T Kielstein, MD @jtkidney.bsky.social · 13/07/2026
„Sometimes a road less travelled is less travelled for a reason.“ at least according to Jerry Seinfeld. I think we should more frequently travel the road of occupational health to screen for #CKD. #CKDatWork: screening for CKD in occupational health academic.oup.com/ckj/article/...
academic.oup.com
#CKDatWork: screening for CKD in occupational health
To the Editor,
000
Jan T Kielstein, MD @jtkidney.bsky.social · 30/06/2026
#ADVOCATE was not only an acronym but a prediction of who would deal with #Avacopan. Funding is needed to conduct studies that address dosing issues and new formulations intubated patients. Our patients need #advocates to fight for treatment options of severe diseases. www.nejm.org/doi/full/10....
nejm.org
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis | NEJM
The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. In this randomized, controlled trial, we assigned patient...
011
Jan T Kielstein, MD @jtkidney.bsky.social · 29/06/2026
@ndt-era.bsky.social was right on publishing a thrice weekly dosing guidance post-dialysis for #Cefazolin in patients undergoing hemodialysis in 1999 academic.oup.com/ndt/article-.... This comes now handy after publication of the #SNAP-trial @nejm.org www.nejm.org/doi/full/10....
academic.oup.com
Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment
Sir,
000
Jan T Kielstein, MD @jtkidney.bsky.social · 15/06/2026
Extracorporeal blood purification can be useful in intoxication depending on toxicokinetic properties. Maj-Britt Nachtigall and @stephan-aus-b.bsky.social extended the knowledge base on #Chlorprothixene #intoxication treated by high-flux hemodialysis and TPE. karger.com/cnd/article/...
karger.com
Neither Therapeutic Plasma Exchange nor High-Flux Hemodialysis Enhances the Removal of Chlorprothixene in Case of Intoxication despite a Drop in Plasma Levels: A Case Report
Abstract. Introduction: Chlorprothixene is a typical antipsychotic, primarily used in the treatment of psychotic disorders. Overdose may result in severe cardiovascular and central nervous system toxi...
000
Jan T Kielstein, MD @jtkidney.bsky.social · 05/06/2026
Welcome to scientific bouncing castle # 10 at #ERA26 where #TorstenMeyer presents „ShuntWizard-a new smart application for vascular access self-monitoring in HDpatients. Comparison of AVFsounds recorded by smartphone vs e-stethoscope“ a joint project of #Carealytix and #skbs supported by the #NBank.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 05/06/2026
#finrenone becomes another pillar of #CKD treatment - that’s the interpretation of the „Efficacy and safety of finerenone in patients with chronic kidney disease: An dividual participant data pooled analysis (INFINITY)“ data presented at #ERA26
020
Jan T Kielstein, MD @jtkidney.bsky.social · 05/06/2026
Spoiler alert ‼️ Timing is everything. The #NEJM has the #FIND-CKD already online. #GMT is not #CET. www.nejm.org/doi/full/10....
nejm.org
Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...
000
Jan T Kielstein, MD @jtkidney.bsky.social · 05/06/2026
Finding a seat for the presentation of the #FIND-CKD study results at #ERA26 will be challenging.
100
Jan T Kielstein, MD @jtkidney.bsky.social · 05/06/2026
Despite #COMPASS off #TRACK. LBCT at #ERA26. While #COMPASS showed a decrease of cardiovascular mortality under twice daily low dose rivaroxaban this approach in pts with advanced CKD at high cardiovascular risk did not have an impact. The study was prematurely stopped due to major bleeding rates.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 09/04/2026
Olivier Moranne hosting the 7th edition of the Les Arènes de la Plasmaphérèse at @chudenimes.bsky.social campus with an impressive lineup of #apheresis specialists.
040
Jan T Kielstein, MD @jtkidney.bsky.social · 06/03/2026
Happy to engage in a PRO /CON discussion on the role of TPE in ANCA vasculitis in a @ucsandiego.bsky.social meeting . ucsd.cloud-cme.com/course/cours...
010
Jan T Kielstein, MD @jtkidney.bsky.social · 06/03/2026
On the occasion of #World Kidney Day@dgfn.bsky.social members Prof. Eckardt and myself could update the Committee on Health on the @who advised national action plan for early detection and management of kidney disease. It’s time to provide comprehensive, uninterrupted and sustainable kidney care.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 06/03/2026
My mother in law’s coffee filter featured at the Committee on Health of the #Bundestag. When your coffe filter rips you have grinds in the cup - if your kidney filter breaks you have albumin in the urine. The #UACR is easy to do, cost effective and helps to diagnose #CKD (chronic kidney disease).
010
Jan T Kielstein, MD @jtkidney.bsky.social · 21/02/2026
And the winner is - Lower Saxony ! Dr. Hauke Wülfrath and collaborators from Braunschweig and Stuttgart performed an important analysis of PD catheter implantation procedures in Germany over a decade. lnkd.in/dEEb5nXB The highest rate of PD-catheter implantation could be found in Lower Saxony.
000
Reposted by Jan T Kielstein, MD
European Group - International Society for Apheresis @e-isfa.bsky.social · 05/12/2025
Prof. Schmidt-Ott and Prof. Klingel opening the 23rd edition of the #apheresis therapy seminar in #Berlin.
022
Reposted by Jan T Kielstein, MD
European Group - International Society for Apheresis @e-isfa.bsky.social · 05/12/2025
From the ice bear Knut to the bedside - Harald Prüss from @bihatcharite.bsky.social on antibody mediated encephalitis and its treatment by #apheresis.
022
Reposted by Jan T Kielstein, MD
European Group - International Society for Apheresis @e-isfa.bsky.social · 05/12/2025
Vega Goedecke from #Medical School Hannover presenting the baseline data from #EXTINCT #postcovid study to treat #MECSF / #Longcovid with #immonoadsorption. The results of this randomized controlled trial will help to answer many questions of this complex disease.
022
Reposted by Jan T Kielstein, MD
European Group - International Society for Apheresis @e-isfa.bsky.social · 05/12/2025
Reinhard Klingel from Apherese ForschungsInstitut - AFI | Apheresis Research Institute reporting long term follow up of #lipoprotein #apheresis at the 23rd #apheresis therapy seminar. For more details read the accompanying paper link.springer.com/article/10.1...
link.springer.com
Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study - Clinical Research in Cardiology Supplements
Elevated lipoprotein(a) (Lp(a)) has emerged as an important independent cardiovascular risk factor, and causal association has been accepted with adverse outcome in atherosclerotic disease. Lipoprotei...
011
Jan T Kielstein, MD @jtkidney.bsky.social · 25/11/2025
When you combine the research expertise of @helmholtzhzi.bsky.social & clinical expertise of #skbs with the curiosity, energy and brightness of a student you might defend your MD thesis with honors. Congratulations to #Malin-Theres Seffer on her work on seraph 100 @extheramedical.bsky.social
020
Reposted by Jan T Kielstein, MD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 07/11/2025
Got #KidneyWk FOMO like @nephroseeker.medsky.social ? We got you covered with daily coverage of the simultaneous publications! www.nephjc.com/news/kidneyw...
nephjc.com
Kidney Week in Houston: Day 1 — NephJC
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
22010
Jan T Kielstein, MD @jtkidney.bsky.social · 07/11/2025
@robmentz.bsky.social giving the best overview on treatment of heart failure and CKD I ever heard - and this as a cardiologist at #kidneywk
000
Jan T Kielstein, MD @jtkidney.bsky.social · 07/11/2025
This disclosure was the most important one I ever heard, it was also a reminder that collecting data on a global level will have an effect on the personal life of patients and their families. Thanks for a memorable talk @saezlab.bsky.social
000
Jan T Kielstein, MD @jtkidney.bsky.social · 07/11/2025
Congratulations to @rkramann.bsky.social for receiving the ASN-American Heart Association Donald W. Seldin Young Investigator Award.
010
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Great start of #kidneywk but there are several people from around the world missing - best epitomized by the the absence of social media wizzard @nephroseeker.medsky.social. Hope to see you at #ERA.
120
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Up the blood pressure targets to prevent frail patients from going down! Andrew C. Nixon nicely explaining why frail patients do not benefit from SPRINT blood pressure targets.
030
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Harbir Singh Kohli presenting a nice summary of Challenges in Hypertension Management in Patients Receiving Dialysis at #kidneywk
110
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Always nice to meet Olivier Moranne from @chudenimes.bsky.social. Looking forward to the 2026 edition of arenesdelaplasma.org
000
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
One way to keep your workforce healthy - care for their kidneys! Happy to present „Evaluating the Economic Impact of CKD on Germany's Health Care System: A 2023 Claims Data Analysis“ at #kidneywk
010
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
„IgAN is a B cell disorder“ - quite a statement but great results of the ORIGIN-3 trial. Kind of cheeky of the #FDA to advise against showing eGFR results.
010
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Hiddo Heerspink presenting results of #FINE-ONE at #kidneywk - hope for patients with type 1 diabetes and #CKD
010
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
Slides specifically for @bmg-bund.bsky.social that it indeed makes sense to screen for #CKD presented at the #kidenywk
000
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
A title well chosen on many levels at #kidneywk
000
Jan T Kielstein, MD @jtkidney.bsky.social · 06/11/2025
One of the most important statements of Prabir Roy-Chaudhry kicking off ASN #KidneyWk
000
Jan T Kielstein, MD @jtkidney.bsky.social · 02/10/2025
Happy to see a whole session at the @dgfn.bsky.social annual meeting dedicated to #apheresis.
020
Reposted by Jan T Kielstein, MD
Boback Ziaeian @boback.bsky.social · 26/08/2025
Going to add this to my lecture slides.
02915
Jan T Kielstein, MD @jtkidney.bsky.social · 12/08/2025
Can we safe water and still do HDF? Check out our report on #AutoFlow regulated dialysate flow in the setting of online #HDF onlinelibrary.wiley.com/doi/10.1111/...
000
Jan T Kielstein, MD @jtkidney.bsky.social · 24/07/2025
New data from the World apheresis registry show an increase in #apheresis procedures for neurological diseases. While the total number of procedures did not increase #myasthenia gravis, #Guillain-Barré Syndrome, #multiple sclerosis, #CIDP and #NMOSD were on the rise. www.trasci.com/article/S147...
trasci.com
The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise
Apheresis is used for the treatment of many different diseases, especially when conventional therapy lacks efficacy. There are however some diseases in which apheresis is accepted as first line therap...
120
Jan T Kielstein, MD @jtkidney.bsky.social · 17/07/2025
Next session @ #ISFA 2025 on liver failure.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 17/07/2025
Hope that one day we can synchronize #apheresis therapy as perfectly as the artists synchronize dancing and percussion during the opening ceremony of the 15th #ISFA World Congress.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 17/07/2025
Ranistha Ratanarat giving a comprehensive overview of adsorptive trechnologiea in #sepsis at #ISFA 2025.
010
Jan T Kielstein, MD @jtkidney.bsky.social · 17/07/2025
#sepsis remains one of the areas with the highest research activity on extracorporeal techniques but with the lowest number of positive RCTs. Excellent overview by Rasheed A. Balogun at #ISFA 2025.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 17/07/2025
Getting ready for #ISFA world congress of apheresis.
000
Jan T Kielstein, MD @jtkidney.bsky.social · 09/07/2025
A happy moment, not only for Falko Mohrs, Minister of Science and Innovation and Mayor of Braunschweig Dr. Thorsten Kornblum but especially for pharmacy students at @tu-braunschweig.de that will enjoy the new building fro 2027 on. Teaching and science in pharmacy have a new home.
021
Jan T Kielstein, MD @jtkidney.bsky.social · 05/07/2025
A firework of mechanistic data by @rebeccaherzog.bsky.social on how negative effects of glucose in #peritoneal dialysis could be attenuated.
040
Jan T Kielstein, MD @jtkidney.bsky.social · 05/07/2025
Kerstin Amann from @fau.de presenting data from the #GRIP There are almost 2,500 peritoneal samples waiting to be analyzed. I am confident that the 1st International Meeting on Cellular and Molecular Peritoneal Dialysis Research will help foster collaboration in getting this done.
020
Jan T Kielstein, MD @jtkidney.bsky.social · 05/07/2025
@ms-balzer.bsky.social with great slides and even better content talking about single-cell transscriptomics at 1st International Meeting on Cellular and Molecular Peritoneal Dialysis Research.
030
Jan T Kielstein, MD @jtkidney.bsky.social · 05/07/2025
Switching gears and going from genetics to epigenetics with Raffaele Strippoli at 1st International Meeting on Cellular and Molecular Peritoneal Dialysis Research.
040